MCHR1 antagonists are provided having the following Formula I: wherein A
1 and A
2 are independently C or N; E is C or N; D
1 is a bond, -CR
8 R
9 X-, -XCR
8 R
9 -, -CHR
8 CHR
9 -, -CR
10 =CR
10' -, -C≡C-, or 1,2-cyclopropyl; X is O, S or -NR
11 ; R
1 , R
2 , and R
3 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, lower cycloalkoxy, -CF
3 , -OCF
3 , -OR
12 and -SR
12 ; G is O or S; D
2 is lower alkyl, lower cycloalkyl, lower alkylcycloalkyl, lower cycloalkylalkyl, lower cycloalkoxyalkyl or lower alkycycloalkoxy; Z
1 and Z
2 are independently hydrogen, halogen, lower alkyl, lower cycloalkyl, lower alkoxy, lower cycloalkoxy, halo, -CF
3 , -OCONR
14 R
14' , -CN, -CONR
14 R
14' , -SOR
12 , -SO
2 R
12 , -NR
14 COR
14' , -NR
14 CO
2 R
14' , -CO
2 R
12 , NR
14 SO
2 R
12 or -COR
12 provided that if Z
1 is -CH
3 and one of R
1 , R
2 , or R
3 is F, then Z
2 cannot be H;; R
5 , R
6 , and R
7 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, -CF
3 , -SR
12 , lower alkoxy, lower cycloalkoxy, -OCH
2 OMe, -CN, -CONR
14 R
14' , SOR
12 , SO
2 R
12 , NR
14 COR
14' , NR
14 CO
2 R
12 , CO
2 R
12 , NR
14 SO
2 R
12 and -COR
12 ; R
8 , R
9 , R
10 , R
10' , R
11 are independently hydrogen or lower alkyl; R
12 is lower alkyl or lower cycloalkyl; and R
14 and R
14' are independently H, lower alkyl, lower cycloalkyl or R
14 and R
14' together with the N to which they are attached form a ring having 4 to 7 atoms. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.